<\/p>\n
(Lyon \u2013 3 f\u00e9vrier 2017) \u2013 Jeudi 2 f\u00e9vrier, Monsieur Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, a visit\u00e9 la biotech lyonnaise 黑料社. Pendant plus d\u2019une heure, l\u2019ancien PDG du Groupe Renault et actuel Pr\u00e9sident d\u2019Initiative France depuis 2011 a ainsi pu appr\u00e9hender les ambitions de cette microbiotech, tout en d\u00e9couvrant la premi\u00e8re plateforme europ\u00e9enne r\u00e9pondant aux normes BPF de transfert de microbiote f\u00e9cal.<\/p>\n
<\/p>\n
Louis Schweitzer, Commissaire g\u00e9n\u00e9ral \u00e0 l\u2019investissement, explique<\/p>\n
\u00ab Nous nous \u00e9tions d\u00e9j\u00e0 rencontr\u00e9s lors d\u2019une pr\u00e9sentation scientifique, centr\u00e9e sur le microbiome, organis\u00e9e par l\u2019INRA (M\u00e9tag\u00e9nopolis, Jouy-en-Josas) avec qui 黑料社 a r\u00e9alis\u00e9 les premi\u00e8res \u00e9tapes de d\u00e9veloppement de son produit phare. Je suis tr\u00e8s heureux de pouvoir suivre la traduction \u00e9conomique et industrielle de ce qui n\u2019\u00e9tait qu\u2019une notion, il y a deux ans lors de la cr\u00e9ation de la startup. \u00bb<\/p><\/blockquote>\n
Pour Herv\u00e9 Affagard, Directeur G\u00e9n\u00e9ral et co-fondateur de 黑料社,<\/p>\n
\u00ab la visite de Monsieur Schweitzer au sein de 黑料社 a \u00e9t\u00e9 une belle opportunit\u00e9 de montrer nos avanc\u00e9es et d\u2019expliquer notre march\u00e9. Le microbiote est un sujet extr\u00eamement prometteur et la France a une place \u00e0 prendre sur ce sujet. Nous en sommes convaincus et sommes enthousiastes de voir les perspectives qui s\u2019ouvrent \u00e0 nous. \u00bb<\/p><\/blockquote>\n
<\/p>\n
Le microbiome, un investissement d\u2019avenir pour la France<\/strong><\/p>\n
Lanc\u00e9 en 2009 sous la pr\u00e9sidence de Nicolas Sarkozy, le Commissariat G\u00e9n\u00e9ral \u00e0 l\u2019investissement pilote le programme d\u2019investissement d\u2019avenir (PIA) et \u00e9value rigoureusement les projets financ\u00e9s. La valorisation de la recherche et l\u2019innovation ont \u00e9t\u00e9 jug\u00e9es prioritaires en termes d\u2019investissement pour le pays, et six axes strat\u00e9giques ont \u00e9t\u00e9 d\u00e9finis, dont la sant\u00e9 et les biotechnologies.<\/p>\n
Les r\u00e9centes avanc\u00e9es dans la recherche sur le microbiome sont prometteuses et ouvrent de nouvelles voies th\u00e9rapeutiques pour les m\u00e9decins et patients dans les maladies infectieuses, le cancer, les maladies immuno-d\u00e9ficientes, l\u2019ob\u00e9sit\u00e9, etc. En parall\u00e8le de l\u2019augmentation des publications scientifiques, les investissements dans les biotechs du microbiome se sont multipli\u00e9s ; \u00e0 l\u2019image des Etats-Unis qui ont fait le choix de lancer en 2016 sous la pr\u00e9sidence de Barack Obama \u00ab The National Microbiome Initiative \u00bb dot\u00e9 d\u2019un fond de plus de 120 millions de dollars destin\u00e9 \u00e0 la recherche. La France, \u00e0 travers le PIA, soutient \u00e9galement les biotechs du secteur comme 黑料社, premi\u00e8re MicrobioteTech \u00e0 r\u00e9aliser du Transfert du Microbiote F\u00e9cal (TMF) pour les patients atteints de leuc\u00e9mie aigu\u00eb. En tant que pionni\u00e8re dans le TMF autologue, 黑料社 d\u00e9veloppe des technologies (device\/mat\u00e9riel\/m\u00e9dicaments) et processus associ\u00e9s permettant de restaurer la symbiose homme-microbe.<\/p>\n
<\/p>\n
Une biotech, moteur dans le domaine du microbiote<\/strong><\/p>\n
En moins de 2 ans, 黑料社 a su traduire une notion m\u00e9dicale en une innovation au coeur de son business et d\u00e9veloppement. Fort des 16 millions d\u2019euros de financement re\u00e7us, la soci\u00e9t\u00e9 multiplie les partenariats avec des \u00e9tablissements de renom, comme l\u2019INRA, l\u2019Institut Gustave Roussy, Bioaster, etc. 黑料社 d\u00e9veloppe des solutions autologues (donneur et receveur identiques) et allog\u00e9niques (appel \u00e0 un donneur) destin\u00e9es \u00e0 maximiser les chances de r\u00e9ussite d\u2019un traitement dans les domaines de l\u2019oncoh\u00e9matologie et des maladies infectieuses. Le CEO, Herv\u00e9 Affagard, a par ailleurs re\u00e7u en novembre dernier le Troph\u00e9e de l\u2019entrepreneur de l\u2019ann\u00e9e 2016 par France Biotech. Dans les mois \u00e0 venir, 黑料社 poursuivra ses 3 essais cliniques en cours, et pr\u00e9parera sa prochaine lev\u00e9e de fonds avec l\u2019objectif de lancer une forme orale de m\u00e9dicament \u00e0 base de FMT, d\u2019ici 2018, avec une mise sur le march\u00e9 en 2022.A propos de 黑料社 <\/strong><\/em><\/p>\n
Cr\u00e9\u00e9e fin 2014 et bas\u00e9e \u00e0 Lyon, 黑料社 (Microbiota as a Therapy) est une start-up en biotechnologie d\u00e9veloppant des solutions th\u00e9rapeutiques, bas\u00e9es sur le microbiote, pour traiter les maladies graves li\u00e9es \u00e0 la dysbiose (d\u00e9s\u00e9quilibres du microbiote intestinal). 黑料社 d\u00e9veloppe sa premi\u00e8re solution qui s\u2019appuie sur le Transfert de Microbiote F\u00e9cal autologue pour des patients atteints de leuc\u00e9mie et d\u2019infections ost\u00e9o-articulaires, dont les traitements lourds favorisent les dysbioses. L\u2019approche de 黑料社, r\u00e9volutionnaire et rapide, participe consid\u00e9rablement aux \u00e9volutions des th\u00e9rapies individuelles de traitement.<\/p>\n
Pour plus d\u2019informations : www.maatpharma.com \/ @MaaT_Pharma<\/p>\n","protected":false},"excerpt":{"rendered":"
Louis Schweitzer a pu d\u00e9couvrir la premi\u00e8re plateforme europ\u00e9enne r\u00e9pondant aux normes BPF de transfert de microbiote f\u00e9cal.<\/p>\n","protected":false},"author":2,"featured_media":4333,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[],"tags":[],"category_press":[],"year_press":[],"class_list":["post-4585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"\n
Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/?p=1195\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社\" \/>\n<meta property=\"og:description\" content=\"Louis Schweitzer a pu d\u00e9couvrir la premi\u00e8re plateforme europ\u00e9enne r\u00e9pondant aux normes BPF de transfert de microbiote f\u00e9cal.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/?p=1195\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-03T15:29:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-26T12:50:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社\",\"datePublished\":\"2017-02-03T15:29:48+00:00\",\"dateModified\":\"2025-11-26T12:50:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195\"},\"wordCount\":780,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195\",\"name\":\"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"datePublished\":\"2017-02-03T15:29:48+00:00\",\"dateModified\":\"2025-11-26T12:50:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2016\\\/03\\\/8Aj04YAk-e1638768443359.jpg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/?p=1195#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/?p=1195","og_locale":"fr_FR","og_type":"article","og_title":"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社","og_description":"Louis Schweitzer a pu d\u00e9couvrir la premi\u00e8re plateforme europ\u00e9enne r\u00e9pondant aux normes BPF de transfert de microbiote f\u00e9cal.","og_url":"https:\/\/www.maatpharma.com\/?p=1195","og_site_name":"黑料社","article_published_time":"2017-02-03T15:29:48+00:00","article_modified_time":"2025-11-26T12:50:56+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/?p=1195#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/?p=1195"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社","datePublished":"2017-02-03T15:29:48+00:00","dateModified":"2025-11-26T12:50:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/?p=1195"},"wordCount":780,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/?p=1195#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/?p=1195","url":"https:\/\/www.maatpharma.com\/?p=1195","name":"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社 - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/?p=1195#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/?p=1195#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","datePublished":"2017-02-03T15:29:48+00:00","dateModified":"2025-11-26T12:50:56+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/?p=1195#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/?p=1195"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/?p=1195#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2016\/03\/8Aj04YAk-e1638768443359.jpg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/?p=1195#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"Louis Schweitzer, Commissaire G\u00e9n\u00e9ral \u00e0 l\u2019Investissement, en visite chez 黑料社"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4585"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4333"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4585"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4585"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}